French National Institute of Health and Medical Research:製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C12320)
◆英語タイトル:French National Institute of Health and Medical Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12320
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年12月
◆ページ数:88
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
French National Institute of Health and Medical Research (INSERM) is a biomedical research institute that conducts research in biology, medicine and public health. The institute offers research in the therapeutic areas of neurosciences, cognitive sciences, neurology, psychiatry, cancer, immunology, inflammation, genetics, cancer, infectiology and microbiology, physiopathology, public health, health technologies, metabolism, cell biology and immunology, among others. It provides services in the areas of human diseases and research findings to the medical community, and to both national and international partners. INSERM also conducts translational research and development services. It operates research units and research centers. INSERM is headquartered in Paris, France.

French National Institute of Health and Medical Research – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
French National Institute of Health and Medical Research, Medical Devices Deals, 2012 to YTD 2018 12
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deal Details 18
Venture Financing 18
Therachon Raises USD60 Million in Mezzanine Financing 18
ILiAD Biotech Raises USD0.6 Million in Venture Financing 20
Step Pharma Raises Additional USD10.1 Million in Series A Financing 21
ILiAD Biotech Raises USD4.7 Million in Financing 23
ILiAD Biotech Raises USD1.2 Million in Venture Financing 24
Therachon Raises Additional USD5 Million in Series A Financing Round 25
ILiAD Biotech Raises USD0.5 Million in Venture Financing 27
ILiAD Biotech Raises USD1 Million in Venture Financing 28
Inception IBD Raises USD14.1 Million in Series A Financing 29
ILiAD Biotech Raises USD0.6 Million in Venture Financing 30
Therachon Raises USD35 Million in Series A Financing 31
Eyevensys Secures Venture Funding 32
Sensorion Raises USD4.6 Million in Venture Financing 33
AAVLife Raises US$12 Million In Series A Financing 34
Aelis Farma Raises USD1.7 Million in Venture Financing 35
Inotrem Raises US$25 Million In Series A Financing 36
Hemarina Raises US$8 Million In Series B Financing 38
Eyevensys Raises US$2 Million In First Round Of Financing 39
Partnerships 40
Telix Pharma Enters into Research Agreement with INSERM and ARRONAX 40
Genisphere Enters into Agreement with Inserm 41
TxCell Enters into R&D Agreement with Inserm Transfert 42
Evotec Enters into Research Agreement with Inserm Transfert 43
Pierre Fabre Medicament Partners with Inserm Transfert 44
AstraZeneca Enters into Research Agreement with Inserm 45
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 46
Mifcare Enters into Agreement with Inserm 47
DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 48
Roche, ANRS, Baylor Researh Institute And Inserm Transfert Enter Into Co-Development Agreement For Therapeutic Vaccines 50
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 52
Licensing Agreements 54
OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 54
Stimunity Enters into Licensing Agreement with Inserm Transfert and Institut Curie 55
ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 56
TargEDys Enters into Licensing Agreement with Inserm Transfert, University of Rouen and Rouen University Hospital 57
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 58
Imcheck Therapeutics Enters Into Licensing Agreement with Inserm Transfert and SATT South East 59
Brainvectis Enters into Licensing Agreement with INSERM 60
ProGeLife Enters into Licensing Agreement with University of Bordeaux and INSERM Transfert 61
Inserm Transfert Enters into Licensing Agreement with HalioDx 62
Ultragenyx Pharma Enters into Licensing Agreement with Inserm Transfert and Institut du Cerveau et de la Moelle Epiniere 63
IntegraGen Enters into Licensing Agreement with Inserm 65
AAVLife Amends Licensing Agreement with Inserm Transfert 66
Inotrem Enters into Licensing Agreement with University of Lorraine and INSERM 67
Acticor Biotech Enters into Licensing Agreement with Inserm Transfert 68
PEP-Therapy Enters into Agreement with Inserm Transfert, Institut Curie and Pierre and Marie 69
GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 70
Anagenesis Biotech Enters into Licensing Agreement with Inserm Transfert and AFM 71
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 72
GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 74
ILiAD Biotech Enters Into Licensing Agreement With Inserm Transfert And Institut Pasteur De Lille For Bordetella Pertussis Vaccine Technology 76
Equity Offering 77
Horama Spin off from Inserm Transfert 77
French National Institute of Health and Medical Research – Key Competitors 78
French National Institute of Health and Medical Research – Key Employees 79
French National Institute of Health and Medical Research – Locations And Subsidiaries 80
Head Office 80
Other Locations & Subsidiaries 80
Affiliate 80
Recent Developments 81
Government and Public Interest 81
Sep 03, 2018: Gene-hunters make sense of a new immune disease 81
Aug 31, 2018: Novel brain network linked to chronic pain in Parkinson’s disease 83
May 02, 2018: Discovery of a first genetic cause of Whipple’s disease 84
Apr 26, 2018: Discovery of a future therapy for hemoglobinopathies 85
Dec 20, 2017: NORD Awards Five New Grants for Rare Disease Research 86
Other Significant Developments 87
Aug 20, 2018: Bioengineered tooth replacement opens doors to new therapies 87
Appendix 88
Methodology 88
About GlobalData 88
Contact Us 88
Disclaimer 88

List of Tables
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Key Facts 2
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
French National Institute of Health and Medical Research, Deals By Therapy Area, 2012 to YTD 2018 10
French National Institute of Health and Medical Research, Medical Devices Deals, 2012 to YTD 2018 12
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Therachon Raises USD60 Million in Mezzanine Financing 18
ILiAD Biotech Raises USD0.6 Million in Venture Financing 20
Step Pharma Raises Additional USD10.1 Million in Series A Financing 21
ILiAD Biotech Raises USD4.7 Million in Financing 23
ILiAD Biotech Raises USD1.2 Million in Venture Financing 24
Therachon Raises Additional USD5 Million in Series A Financing Round 25
ILiAD Biotech Raises USD0.5 Million in Venture Financing 27
ILiAD Biotech Raises USD1 Million in Venture Financing 28
Inception IBD Raises USD14.1 Million in Series A Financing 29
ILiAD Biotech Raises USD0.6 Million in Venture Financing 30
Therachon Raises USD35 Million in Series A Financing 31
Eyevensys Secures Venture Funding 32
Sensorion Raises USD4.6 Million in Venture Financing 33
AAVLife Raises US$12 Million In Series A Financing 34
Aelis Farma Raises USD1.7 Million in Venture Financing 35
Inotrem Raises US$25 Million In Series A Financing 36
Hemarina Raises US$8 Million In Series B Financing 38
Eyevensys Raises US$2 Million In First Round Of Financing 39
Telix Pharma Enters into Research Agreement with INSERM and ARRONAX 40
Genisphere Enters into Agreement with Inserm 41
TxCell Enters into R&D Agreement with Inserm Transfert 42
Evotec Enters into Research Agreement with Inserm Transfert 43
Pierre Fabre Medicament Partners with Inserm Transfert 44
AstraZeneca Enters into Research Agreement with Inserm 45
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 46
Mifcare Enters into Agreement with Inserm 47
DBV Technologies Enters Into Research Agreement With Inserm For Viaskin 48
Roche, ANRS, Baylor Researh Institute And Inserm Transfert Enter Into Co-Development Agreement For Therapeutic Vaccines 50
Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 52
OSE Immunotherapeutics Enters into Option Agreement with Inserm Transfert 54
Stimunity Enters into Licensing Agreement with Inserm Transfert and Institut Curie 55
ProQR Therapeutics Signs License Agreement with Inserm Transfert and Assistance-Publique-Hopiteaux de Paris 56
TargEDys Enters into Licensing Agreement with Inserm Transfert, University of Rouen and Rouen University Hospital 57
ElsaLys Biotech Enters into Licensing Agreement with Inserm Transfert 58
Imcheck Therapeutics Enters Into Licensing Agreement with Inserm Transfert and SATT South East 59
Brainvectis Enters into Licensing Agreement with INSERM 60
ProGeLife Enters into Licensing Agreement with University of Bordeaux and INSERM Transfert 61
Inserm Transfert Enters into Licensing Agreement with HalioDx 62
Ultragenyx Pharma Enters into Licensing Agreement with Inserm Transfert and Institut du Cerveau et de la Moelle Epiniere 63
IntegraGen Enters into Licensing Agreement with Inserm 65
AAVLife Amends Licensing Agreement with Inserm Transfert 66
Inotrem Enters into Licensing Agreement with University of Lorraine and INSERM 67
Acticor Biotech Enters into Licensing Agreement with Inserm Transfert 68
PEP-Therapy Enters into Agreement with Inserm Transfert, Institut Curie and Pierre and Marie 69
GlaxoSmithKline Enters Into Licensing Agreement With Inserm Transfert For Monoclonal Antibodies 70
Anagenesis Biotech Enters into Licensing Agreement with Inserm Transfert and AFM 71
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 72
GenSight Biologics Enters into Licensing Agreement with Inserm Transfert 74
ILiAD Biotech Enters Into Licensing Agreement With Inserm Transfert And Institut Pasteur De Lille For Bordetella Pertussis Vaccine Technology 76
Horama Spin off from Inserm Transfert 77
French National Institute of Health and Medical Research, Key Competitors 78
French National Institute of Health and Medical Research, Key Employees 79
French National Institute of Health and Medical Research, Subsidiaries 80
French National Institute of Health and Medical Research, Affiliate 80

List of Figures
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
French National Institute of Health and Medical Research, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
French National Institute of Health and Medical Research, Medical Devices Deals, 2012 to YTD 2018 12

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ French National Institute of Health and Medical Research:製薬・医療:M&Aディール及び事業提携情報(French National Institute of Health and Medical Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆